Pan-immune-inflammation value as a novel predictor of pathological response to neoadjuvant chemotherapy combined with anti-PD-1 therapy in esophageal squamous cell carcinoma: a multicenter real-world retrospective clinical study.

ABSTRACT:

Background

Current biomarkers for predicting pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma (ESCC) remain limited.

Objective

This study investigates the potential of the pan-immune-inflammation value (PIV) as a biomarker for predicting pathological response after neoadjuvant chemoradiotherapy combined with anti-programmed death protein-1 (PD-1) therapy in ESCC.

Design

A multicenter, real-world, retrospective clinical study conducted across five centers in Southern China (January 2021-March 2024).

Methods

A multicenter retrospective study included 334 patients with ESCC, divided into pathological complete response (pCR) and non-pathological complete response (non-pCR) groups. Clinical and laboratory data were analyz

SUBMITTER: Huang JS 

PROVIDER: S-EPMC12579197 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature